written on 09.06.2014
Tags:
,

Court limits Canada's power over generic drug prices

TAGS: ,

A federal court in Canada has now agreed with the industry that the country's price setting board has assumed too much authority and severely curtailed its ability to control prices over generic drugs in a case centered on Novartis' generic drug company Sandoz, and a unit of Teva Pharmaceutical Industries, which started as Ratiopharm.

Latest Report